Friday, April 08, 2016

Are common painkillers more dangerous than we think?


We can buy common painkillers over-the-counter at  a pharmacy or even be prescribed them in copious amounts for the treatment  of difficult conditions such as colds, flu, pain, inflammation, and fever. However, all drugs come with side effects, such as increased blood pressure or an increased risk of ulcers. A new study has gathered all the information on each side effect of each common painkiller and its effect on patients with different health conditions (such as diabetes or heart-related diseases).
What you need to know about NSAIDs:
  • NSAIDs is an abbreviation for Nonsteroidal Anti-Inflammatory Drugs and is used to treat a wide range of diseases, in particular, disorders in the muscular and bone system, where the drug counteracts swelling, pain and limitations in movement associated with inflammation.
  • NSAIDs are not antibiotics and therefore do not help to fight infections caused by bacteria.
  • NSAIDs are in Denmark sold both in low doses (Ibuprofen 200 mg/tablet) without a prescription and in higher doses and other types with a prescription.
"It's been well-known for a number of years that newer types of NSAIDs -- what are known as COX-2 inhibitors, increase the risk of heart attacks. For this reason, a number of these newer types of NSAIDs have been taken off the market again. We can now see that some of the older NSAID types, particularly Diclofenac, are also associated with an increased risk of heart attack and apparently to the same extent as several of the types that were taken off the market," says Morten Schmidt, MD and PhD from Aarhus University, who is in charge of the research project. He adds:
"This is worrying because these older types of medicine are frequently used throughout the western world and in many countries available without prescription."
Every year, more than 15 percent of western populations are prescribed painkillers (NSAIDs) and this figure increases with patient age.
The study, which was carried out in collaboration between 14 European universities and hospitals, including a number of leading European heart specialists, was published in the European Heart Journal.
New Guidelines:
This study was conducted with the intention to find out the use of NSAIDs in patients with heart disease. Results from the survey that they gathered has now been used to compile a list of recommendations about what doctors should consider before prescribing painkillers to their patients.
"When doctors issue prescriptions for NSAIDs, they must in each individual case carry out a thorough assessment of the risk of heart complications and bleeding. NSAIDs should only be sold over the counter when it comes with an adequate warning about the associated cardiovascular risks. In general, NSAIDs are not be used in patients who have or are at high-risk of cardiovascular diseases," says another of the authors, Professor in cardiology Christian Torp-Pedersen, Aalborg University, Denmark.
We need to reduce the amount of painkillers being taken:

After seeing the results of this study, the researchers in Denmark have recommended that it would be better for patient safety that the amounts of painkillers prescribed and/or taken should be reduced, not just in Denmark but for all countries who consume more of these drugs. The Danish researchers have already been successful in reducing the consumption of Diclofenac in Denmark. Hopefully, this research will open the door for more research on NSAIDs and their effect on patients with other health conditions so that there will be more efficient guidelines on the prescription of painkillers. 
___________________________
References:
Image: [1] Quotes: [1] Story: [1] 

Continue Reading
No comments
Share:

Sunday, April 03, 2016

Possibility for Future AIDS Vaccine


HIV is a virus that attacks the immune system and weakens your ability to fight incoming infections and diseases. The Human Immunodeficiency Virus currently has no cure but there are currently treatments which are able to help people with the virus to live a prolonged, healthy life. Since there is no cure for HIV, the best way to approach preventing the spread of the virus is by vaccination; enabling the body to fight off the virus before it attacks the immune system. 

Researchers in the USA have been working on developing a vaccine capable of inducing "broadly neutralizing" antibodies that can prevent HIV infections. This new vaccine technique aims to immunize people with a series of different engineered HIV proteins as immunogens to "teach" the immune system to produce broadly neutralizing antibodies against HIV. This in turn, will prepare the immune system to fight off an incoming virus which carries similar proteins to the HIV proteins.

The group of researchers have found that the right precursor ("germline") cells for one kind of HIV broadly neutralizing antibody which is  present in most people, and have described the design of an HIV vaccine germline-targeting immunogen capable of binding those B cells. 


"We found that almost everybody has these broadly neutralizing antibody precursors, and that a precisely engineered protein can bind to these cells that have potential to develop into HIV broadly neutralizing antibody-producing cells, even in the presence of competition from other immune cells," said the study's lead author, William Schief, TSRI professor and director, Vaccine Design of the IAVI Neutralizing Antibody Center at TSRI, in whose lab the engineered HIV vaccine protein was developed.

The human immune system  consists of a large variety of variating precursor B cells so that it is able to respond to a large variety of pathogens (viruses and bacteria). However, this also means that the precursor B cells able to recognize a specific feature on a virus surface are exceedingly rare within the total pool of B cells.  

Our immune system is able to track and hunt down pathogens which carry markers (the proteins on the surface of the virus) for the HIV virus. This advance in research has lead to a phase 1 trial being initiated to clinical trial to test a nanoparticle version of the engineered HIV vaccine protein, the "eOD-GT8 60mer."

"The goal of the clinical study will be to test the safety and the ability of this engineered protein to elicit the desired immune response in humans that would look like the start of broadly neutralizing antibody development," Schief said. "Data from this new study was also important for designing the clinical trial, including the size and the methods of analysis."

In June 2015, researchers from TSRI, IAVI and The Rockefeller University reported that the eOD-GT8 60mer produced antibody responses in mice that showed some of the traits necessary to recognize and inhibit HIV. If the eOD-GT8 60mer performs similarly in humans, additional boost immunogens are thought to be needed to ultimately induce broadly neutralizing antibodies that can block HIV.

This new research has provided a new technique for researchers to determine if other new vaccine proteins can bind their intended precursor B cells. This technique is essential in manufacturing targeted and effective vaccines against HIV and AIDs. 

This research was published in the March 25, 2016 issue of Science, published by AAAS. The paper, by J.G. Jardine at Scripps Research Institute in La Jolla, CA, and colleagues was titled, "HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen."
_____________________________
References:
The Scripps Research Institute. "New findings in humans provide encouraging foundation for upcoming AIDS vaccine clinical trial." ScienceDaily. ScienceDaily, 24 March 2016. 

https://www.sciencedaily.com/releases/2016/03/160324150047.htm

Continue Reading
No comments
Share:
All content copyright © 2016/17 Mariam Zaki unless otherwise noted. Powered by Blogger.